T1 Edition Junior Study

Edition Junior Summary
Download this clinical summary to read about the benefits of Toujeo® in children and adolescents from the age of 6 years in this randomised trial. Edition Junior was a 6 month long, open-label, double arm, parallel group, non-inferiority study in 463 children with T1DM. The aim of the study was to demonstrate non-inferiority of Toujeo® vs insulin glargine 100 U/mL from baseline to Week 26.
This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy.
By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.
Accept and close